CAG
NVCR icon

Crestwood Advisors Group’s NovoCure NVCR Stock Holding History

Crestwood Advisors Group’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$246K Buy
16,228
+415
+3% +$6.28K ﹤0.01% 763
2026
Q1 		$172K Buy
+15,813
New +$198K ﹤0.01% 742

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Crestwood Advisors Group's NVCR Position: Q2 2026 in Review

Crestwood Advisors Group increased its NovoCure (NVCR) stake by 2.6% in Q2 2026, buying an estimated $6.28K and bringing the position to 16,228 shares worth $246K. The position accounts for ﹤0.01% of the portfolio, ranked #763.

Crestwood Advisors Group first reported a position in NVCR in Q1 2026 and has held it in 2 quarters since. 218 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

  • Crestwood Advisors Group held 16,228 shares of NovoCure worth $246K as of Q2 2026.
  • Crestwood Advisors Group bought 415 NovoCure shares in Q2 2026, an estimated $6.28K.
  • NovoCure made up ﹤0.01% of Crestwood Advisors Group's portfolio in Q2 2026, its #763 holding.
  • Crestwood Advisors Group first reported a position in NovoCure in Q1 2026 and has held it in 2 quarters since.
  • 218 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Crestwood Advisors Group's 13F filing for Q2 2026, filed 3 Aug 2026.